Yueren Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yueren Zhou has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Loralee B. Rupp
Center for Health Policy and Health Services Research, Henry Ford Health, Detroit, Michigan
8 shared publications - Mark A. Schmidt
Kaiser Permanente Center for Health Research, 3800 N. Interstate Avenue, Portland, OR 97227, USA
8 shared publications - Mei Lu
School of Medicine Michigan State University East Lansing Michigan USA
8 shared publications - Meng-Hua Tao
Department of Public Health Sciences, Henry Ford Health, Detroit, USA
8 shared publications - Sheri Trudeau
Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan
8 shared publications - Stuart C. Gordon
Division of Gastroenterology and Hepatology Henry Ford Health Detroit Michigan USA
8 shared publications
Latest Publications
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Background:Antiviral treatment for hepatitis C virus (HCV) has been shown to reduce risk of liver cancer, but there are few studies on its impact on the risk of non-liver cancers. We used a large cohort of patients with HCV with extensive follow-up to investigate whether receipt of antiviral therapy affects the risk of extrahepatic cancers.Methods:A total of 17,485 patients with HCV were followed until incidence of lung cancer, non–Hodgkin lymphoma (NHL), breast or prostate cancer, death, or last follow-up. We used multivariable modeling with time-varying covariates and propensity scores to adjust for treatment selection bias; we also applied generalized estimating equations with a multinominal link function for discrete time-to-event data. Death was considered a competing risk.Results:After 15 years of follow-up, we identified 408 incident cases of cancers, namely 140 lung, 72 NHL, 81 breast (female), and 115 prostate cancer cases. Compared with no treatment, patients who receive either direct-acting antivirals or IFN-based treatment had significantly lower risk of lung cancer [HR = 0.35, 95% confidence interval, 0.24−0.52 for achieving sustained virologic response (SVR); HR = 0.34, 95% confidence interval, 0.21−0.55 for treatment failure]. Risk of NHL was reduced only among patients who achieved SVR. There were no significant associations between antiviral therapy and risks of breast and prostate cancers.Conclusions:Antiviral treatment for HCV independently reduced the risk of lung cancer, whereas the protective association with NHL was limited to patients achieving SVRs.Impact:Our findings support the importance of timely initiation antiviral therapy in patients with chronic HCV.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Background:Antiviral treatment for hepatitis C virus (HCV) has been shown to reduce risk of liver cancer, but there are few studies on its impact on the risk of non-liver cancers. We used a large cohort of patients with HCV with extensive follow-up to investigate whether receipt of antiviral therapy affects the risk of extrahepatic cancers.Methods:A total of 17,485 patients with HCV were followed until incidence of lung cancer, non–Hodgkin lymphoma (NHL), breast or prostate cancer, death, or last follow-up. We used multivariable modeling with time-varying covariates and propensity scores to adjust for treatment selection bias; we also applied generalized estimating equations with a multinominal link function for discrete time-to-event data. Death was considered a competing risk.Results:After 15 years of follow-up, we identified 408 incident cases of cancers, namely 140 lung, 72 NHL, 81 breast (female), and 115 prostate cancer cases. Compared with no treatment, patients who receive either direct-acting antivirals or IFN-based treatment had significantly lower risk of lung cancer [HR = 0.35, 95% confidence interval, 0.24−0.52 for achieving sustained virologic response (SVR); HR = 0.34, 95% confidence interval, 0.21−0.55 for treatment failure]. Risk of NHL was reduced only among patients who achieved SVR. There were no significant associations between antiviral therapy and risks of breast and prostate cancers.Conclusions:Antiviral treatment for HCV independently reduced the risk of lung cancer, whereas the protective association with NHL was limited to patients achieving SVRs.Impact:Our findings support the importance of timely initiation antiviral therapy in patients with chronic HCV.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 4 shows characteristics of HCV patients at baseline for breast cancer
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 4 shows characteristics of HCV patients at baseline for breast cancer
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S6 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 6 describes distribution of identified primary NHL cases based on morphology type
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 6 describes distribution of identified primary NHL cases based on morphology type
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 2 describes characteristics of HCV patients at baseline for lung cancer
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 2 describes characteristics of HCV patients at baseline for lung cancer
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 1 shows ICD-O-3 codes used to identify interested primary extrahepatic cancers
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 1 shows ICD-O-3 codes used to identify interested primary extrahepatic cancers
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 5 shows characteristics of HCV patients at baseline for prostate cancer
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 5 shows characteristics of HCV patients at baseline for prostate cancer
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 3 describes characteristics of HCV patients at baseline for NHL
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 3 describes characteristics of HCV patients at baseline for NHL
- 28 August 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (11) , 2025-2031
Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Background: Antiviral treatment for hepatitis C virus (HCV) has been shown to reduce risk of liver cancer, but there are few studies on its impact on the risk of non-liver cancers. We used a large cohort of patients with HCV with extensive follow-up to investigate whether receipt of antiviral therapy affects the risk of extrahepatic cancers. Methods: A total of 17,485 patients with HCV were followed until incidence of lung cancer, non–Hodgkin lymphoma (NHL), breast or prostate cancer, death, or last follow-up. We used multivariable modeling with time-varying covariates and propensity scores to adjust for treatment selection bias; we also applied generalized estimating equations with a multinominal link function for discrete time-to-event data. Death was considered a competing risk. Results: After 15 years of follow-up, we identified 408 incident cases of cancers, namely 140 lung, 72 NHL, 81 breast (female), and 115 prostate cancer cases. Compared with no treatment, patients who receive either direct-acting antivirals or IFN-based treatment had significantly lower risk of lung cancer [HR = 0.35, 95% confidence interval, 0.24−0.52 for achieving sustained virologic response (SVR); HR = 0.34, 95% confidence interval, 0.21−0.55 for treatment failure]. Risk of NHL was reduced only among patients who achieved SVR. There were no significant associations between antiviral therapy and risks of breast and prostate cancers. Conclusions: Antiviral treatment for HCV independently reduced the risk of lung cancer, whereas the protective association with NHL was limited to patients achieving SVRs. Impact: Our findings support the importance of timely initiation antiviral therapy in patients with chronic HCV.
- 28 August 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (11) , 2025-2031
Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Background: Antiviral treatment for hepatitis C virus (HCV) has been shown to reduce risk of liver cancer, but there are few studies on its impact on the risk of non-liver cancers. We used a large cohort of patients with HCV with extensive follow-up to investigate whether receipt of antiviral therapy affects the risk of extrahepatic cancers. Methods: A total of 17,485 patients with HCV were followed until incidence of lung cancer, non–Hodgkin lymphoma (NHL), breast or prostate cancer, death, or last follow-up. We used multivariable modeling with time-varying covariates and propensity scores to adjust for treatment selection bias; we also applied generalized estimating equations with a multinominal link function for discrete time-to-event data. Death was considered a competing risk. Results: After 15 years of follow-up, we identified 408 incident cases of cancers, namely 140 lung, 72 NHL, 81 breast (female), and 115 prostate cancer cases. Compared with no treatment, patients who receive either direct-acting antivirals or IFN-based treatment had significantly lower risk of lung cancer [HR = 0.35, 95% confidence interval, 0.24−0.52 for achieving sustained virologic response (SVR); HR = 0.34, 95% confidence interval, 0.21−0.55 for treatment failure]. Risk of NHL was reduced only among patients who achieved SVR. There were no significant associations between antiviral therapy and risks of breast and prostate cancers. Conclusions: Antiviral treatment for HCV independently reduced the risk of lung cancer, whereas the protective association with NHL was limited to patients achieving SVRs. Impact: Our findings support the importance of timely initiation antiviral therapy in patients with chronic HCV.